NO20072803L - Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer - Google Patents
Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorerInfo
- Publication number
- NO20072803L NO20072803L NO20072803A NO20072803A NO20072803L NO 20072803 L NO20072803 L NO 20072803L NO 20072803 A NO20072803 A NO 20072803A NO 20072803 A NO20072803 A NO 20072803A NO 20072803 L NO20072803 L NO 20072803L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- vegf
- receptor kinase
- growth factor
- vascular endothelial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090420A EP1655297A1 (fr) | 2004-11-03 | 2004-11-03 | Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF) |
PCT/EP2005/011709 WO2006048249A1 (fr) | 2004-11-03 | 2005-10-28 | Nicotinamide pyridinureas utiles comme inhibiteurs de kinase dans le recepteur du facteur de croissance de l'endothelium vasculaire (vegf) |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072803L true NO20072803L (no) | 2007-08-02 |
Family
ID=34928841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072803A NO20072803L (no) | 2004-11-03 | 2007-06-01 | Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1655297A1 (fr) |
JP (1) | JP5069119B2 (fr) |
KR (1) | KR20070085609A (fr) |
CN (1) | CN101056870A (fr) |
AU (1) | AU2005300734A1 (fr) |
BR (1) | BRPI0515725A (fr) |
CA (1) | CA2586265C (fr) |
ES (1) | ES2394324T3 (fr) |
IL (1) | IL182335A0 (fr) |
MX (1) | MX2007005340A (fr) |
NO (1) | NO20072803L (fr) |
RU (1) | RU2007120691A (fr) |
WO (1) | WO2006048249A1 (fr) |
ZA (1) | ZA200705003B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007311591B2 (en) | 2006-10-18 | 2010-10-07 | Pfizer Products Inc. | Biaryl ether urea compounds |
DK2346827T3 (da) * | 2008-08-27 | 2014-02-03 | Leo Pharma As | Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere |
RU2017109664A (ru) | 2009-10-06 | 2019-01-23 | Милленниум Фармасьютикалз, Инк. | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
CA2927901A1 (fr) | 2013-11-11 | 2015-05-14 | Syngenta Participations Ag | Derives de 1 -(pyridazin-3-yl)-imidazolidin-2-one en tant qu'herbicides |
EP3092226B1 (fr) * | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Composés d'imidazole utilisables en tant qu'inhibiteurs de l'irak4 |
DK3466955T3 (da) | 2014-01-13 | 2021-02-01 | Aurigene Discovery Tech Ltd | Fremgangsmåde til fremstilling af oxazol[4,5-b]pyridin og thiazol[4,5-b]pyridinderivater som irak4-hæmmere til behandling af cancer |
PL3600270T3 (pl) | 2017-03-31 | 2023-09-25 | Aurigene Oncology Limited | Związki i kompozycje do leczenia zaburzeń hematologicznych |
EP3704108B1 (fr) | 2017-10-31 | 2024-04-24 | Curis, Inc. | Inhibiteur d'irak4 en combinaison avec un inhibiteur de bcl-2 pour utilisation dans le traitement du cancer |
CN109942544B (zh) * | 2017-12-21 | 2021-06-11 | 中国科学院合肥物质科学研究院 | 一类新型吲唑类衍生物激酶抑制剂 |
CN108467360B (zh) * | 2018-06-22 | 2021-04-30 | 江苏美迪克化学品有限公司 | 一种阿帕替尼的制备方法及其中间体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2003000678A1 (fr) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Derives de cyanoanthranylamide et leur utilisation comme medicament |
PL364478A1 (en) * | 2001-05-08 | 2004-12-13 | Schering Aktiengesellschaft | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
PL374610A1 (en) * | 2002-07-31 | 2005-10-31 | Schering Aktiengesellschaft | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
EP1655295A1 (fr) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF |
EP1657241A1 (fr) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF |
-
2004
- 2004-11-03 EP EP04090420A patent/EP1655297A1/fr not_active Withdrawn
-
2005
- 2005-10-28 ES ES05806225T patent/ES2394324T3/es active Active
- 2005-10-28 BR BRPI0515725-0A patent/BRPI0515725A/pt not_active IP Right Cessation
- 2005-10-28 MX MX2007005340A patent/MX2007005340A/es not_active Application Discontinuation
- 2005-10-28 JP JP2007538358A patent/JP5069119B2/ja not_active Expired - Fee Related
- 2005-10-28 CA CA2586265A patent/CA2586265C/fr not_active Expired - Fee Related
- 2005-10-28 WO PCT/EP2005/011709 patent/WO2006048249A1/fr active Application Filing
- 2005-10-28 EP EP05806225A patent/EP1807416B1/fr active Active
- 2005-10-28 KR KR1020077012381A patent/KR20070085609A/ko not_active Application Discontinuation
- 2005-10-28 AU AU2005300734A patent/AU2005300734A1/en not_active Abandoned
- 2005-10-28 CN CNA2005800381303A patent/CN101056870A/zh active Pending
- 2005-10-28 RU RU2007120691/04A patent/RU2007120691A/ru unknown
-
2007
- 2007-03-29 IL IL182335A patent/IL182335A0/en unknown
- 2007-06-01 NO NO20072803A patent/NO20072803L/no not_active Application Discontinuation
- 2007-06-01 ZA ZA200705003A patent/ZA200705003B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2007120691A (ru) | 2008-12-10 |
KR20070085609A (ko) | 2007-08-27 |
ES2394324T3 (es) | 2013-01-30 |
EP1807416A1 (fr) | 2007-07-18 |
CA2586265C (fr) | 2013-08-06 |
CA2586265A1 (fr) | 2006-05-11 |
MX2007005340A (es) | 2007-08-17 |
JP2008518893A (ja) | 2008-06-05 |
EP1655297A1 (fr) | 2006-05-10 |
IL182335A0 (en) | 2007-07-24 |
EP1807416B1 (fr) | 2012-08-29 |
AU2005300734A1 (en) | 2006-05-11 |
BRPI0515725A (pt) | 2008-08-05 |
WO2006048249A1 (fr) | 2006-05-11 |
CN101056870A (zh) | 2007-10-17 |
JP5069119B2 (ja) | 2012-11-07 |
ZA200705003B (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072803L (no) | Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer | |
NO20072802L (no) | Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer | |
NO20072804L (no) | Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer | |
WO2007050783A3 (fr) | Fasudil en polytherapies pour traiter l'hypertension arterielle pulmonaire | |
CL2008003691A1 (es) | Compuestos derivados de 4-(fenil o piridin) pirimidina, inhibidores de la elastasa neutrofila humana; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de hipertension arterial pulmonar, epoc, enfisema pulmonar, entre otras. | |
NO20090267L (no) | Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20071593L (no) | Pyrimidinderivater | |
ATE432260T1 (de) | Pyridinderivate als pkc-theta-hemmer | |
NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
NO20064519L (no) | Karbolinderivater som er anvendbare ved inhibering av angiogenese | |
NO20072747L (no) | Fremgangsmate for fremstilling av indazolforbindelser | |
NO20076648L (no) | Novel thiophene derivatives | |
NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
ATE457311T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine | |
NO20082793L (no) | Nye tiofenderivater | |
NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
DK1543011T3 (da) | Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander | |
NO20065948L (no) | Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser | |
NO20052028L (no) | Pyridinderivater som CB2 reseptor modulatorer | |
DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
NO20075298L (no) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
NO20064771L (no) | 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |